Renalytix (LSE:RENX) non-executive chair Julian Baines MBE plans to leave the board on 31 December 2026. The kidney disease diagnostics company recently completed a £10.5m fundraise and signed a multi-year Partnership with Quest Diagnostics, and it says a search for his successor is already under way.
What was announced
On 28 September 2026 Renalytix plc (LSE:RENX), a precision medicine diagnostics company focused on kidney disease, announced that its non-executive chair, Julian Baines MBE, intends to step down with effect from 31 December 2026.
Mr Baines has chaired Renalytix twice. He first held the role of non-executive chairman from March 2018 to June 2020, covering the period in which the company listed in November 2018, and he returned to the board in November 2024.
The company said it is actively interviewing senior industry executives for the chair role. It expects to put proposals to the board shortly and will update shareholders after that. No candidate has been named, and the announcement does not set out interim arrangements should an appointment not be finalised by the end of the year.
Why now
Mr Baines tied the timing of his departure to two recent milestones. Renalytix has completed a fundraising that brought in £10.5m gross, and it has agreed a multi-year partnership with Quest Diagnostics covering distribution of its kidneyintelX.dkd test and strategic partnerships in the US. The announcement does not repeat the terms of either transaction.
"With the recent signing of our multi-year partnership with Quest Diagnostics... I feel it is an appropriate time for me to stand down," Mr Baines said. He added: "I firmly believe that kidneyintelX.dkd will revolutionise the way clinicians manage kidney disease," and said the Quest partnership gives "the opportunity to rapidly rollout kidneyintelX.dkd testing services across the United States."
Chief executive James McCullough thanked Mr Baines "for Julian's support over the many years" and said: "I am delighted by the quality of the candidates with whom we are already engaging for the Chairman position."
Background
The company's lead product, kidneyintelX.dkd, is an AI-enabled test designed to help clinicians manage diabetic kidney disease. According to Renalytix, the test has US Food and Drug Administration authorisation and Medicare reimbursement, and it is commercially available across the United States. Renalytix puts the number of people with diabetic kidney disease at about 15 million in the US and about 8 million in the UK.
In Mr Baines's words, the Quest Diagnostics agreement is a route to rolling out testing rapidly across the US. The announcement does not quantify how quickly testing volumes and Revenue might build through the partnership, and it contains no revenue guidance, cash position or cash runway figures. Renalytix's shares are quoted in London and, through the RNLXY line, on the US OTCQB market.
Beyond the timing Mr Baines described, the announcement gives no other reason for his departure. It also does not say whether any other board changes are planned alongside the appointment of a new chair, or whether the new chair is expected to come from the diagnostics industry specifically. The only description of the candidates is that they are senior industry executives.
What to watch next
Shareholders can expect a further announcement once the board has chosen a new chair. That announcement should include the candidate's background and any disclosures required under the rules that apply to the company's listing. Other points to watch are any updates from Renalytix on the progress of the Quest Diagnostics roll-out, early testing volumes, and how the proceeds of the £10.5m raise are being used. The announcement does not give a timetable for the next financial update.



_11_18_2026_14_37_47_487896.jpg)


Please wait processing your request...